Grace Therapeutics Announces Presentation of Abstract at SVIN Annual Meeting: Novel GTx-104 Trial Results to be Presented.

Grace Therapeutics announced an abstract for its Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH has been accepted for presentation at the Society of Vascular and Interventional Neurology annual meeting. The trial compares the safety and tolerability of GTx-104 (nimodipine injection for IV infusion) to oral nimodipine in patients with aneurysmal subarachnoid hemorrhage. The presentation will be given by Thomas P Bleck, MD, on November 21, 2025.